Objective response (CR+PR) rate of subjects given Trisenox 2 years [clinicaltrials_resource:d75d883bb8c08c5e2a83d3f355bf249d]
To estimate the objective response (CR+PR) rate (as defined by the Gynecologic Oncology Group [GOG] RECIST Criteria)of Trisenox® in women with recurrent or metastatic endometrial cancer when administered at 0.25 mg/kg/day for 5 consecutive days (D1-5) every 4 weeks.
clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]
Objective response (CR+PR) rate of subjects given Trisenox 2 years [clinicaltrials_resource:d75d883bb8c08c5e2a83d3f355bf249d]
To estimate the objective response (CR+PR) rate (as defined by the Gynecologic Oncology Group [GOG] RECIST Criteria)of Trisenox® in women with recurrent or metastatic endometrial cancer when administered at 0.25 mg/kg/day for 5 consecutive days (D1-5) every 4 weeks.
Bio2RDF identifier
d75d883bb8c08c5e2a83d3f355bf249d
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:d75d883bb8c08c5e2a83d3f355bf249d
measure [clinicaltrials_vocabulary:measure]
Objective response (CR+PR) rate of subjects given Trisenox
time frame [clinicaltrials_vocabulary:time-frame]
description
To estimate the objective resp ...... ive days (D1-5) every 4 weeks.
identifier
clinicaltrials_resource:d75d883bb8c08c5e2a83d3f355bf249d
title
Objective response (CR+PR) rate of subjects given Trisenox 2 years
@en
type
label
Objective response (CR+PR) rat ...... d883bb8c08c5e2a83d3f355bf249d]
@en